Kirsten

UCI MIND Faculty Member Elizabeth Head, PhD was featured in the Akron Beacon Journal: I recently interviewed Dr. Elizabeth Head, a [professor and] neuropathology core co-investigator at the Alzheimer’s Disease Research Center at University of California, Irvine. While she collaborates with researchers studying Alzheimer’s in the general population, her research is focused specifically on the Down syndrome population. Her team and others are conducting longitudinal studies, in which volunteers with Down syndrome participate for many years, discovering relevant data that are the building blocks for future treatments. Read the full article here >

The post Alzheimer’s research in people with Down syndrome benefits all appeared first on UCI MIND.

The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines. AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines. A liposomal vaccine prompted #antibody response against phospho-tau. Preclinical data bode well for another tau vaccine; first trial slated for next year. Read more >

The post Two New Stabs at Vaccinating People Against Pathologic Tau appeared first on UCI MIND.

UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results. The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below). Read his commentary here > Read the full article here >

The post Dare We Say Consensus Achieved: Lecanemab Slows the Disease appeared first on UCI MIND.

Eat This, Not That! “According to a study performed by UCI MIND and presented at the American Association for the Advancement of Science, there’s a connection between longevity and drinking a moderate amount of alcohol. (Let’s stress …

When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage of the FDA’s decision made the public less willing to volunteer for Alzheimer’s pharmaceutical trials. The study was conducted by the UCI Institute for Memory Impairments and Neurological Disorders, known as UCI MIND. It appears in the Journal of Alzheimer’s Disease. (Link to abstract) The UCI team performed the survey in tandem with the FDA’s spring…

The post Controversial Alzheimer’s drug approval sparks surprising impact appeared first on UCI MIND.

Healthline – “There is a lot of evidence that links sleep apnea to Alzheimer’s disease risk,” added Bryce Mander, Ph.D, assistant professor, Psychiatry & Human Behavior, School of Medicine at the University of California, Irvine. “But there i…

“Researchers are working hard to find a cure to Alzheimer’s disease … Through their efforts, new research and studies have proven helpful in ways to prevent the disease and even possible treatments. We learn about these findings from our pa…